ImmunityBio (NASDAQ:IBRX) Stock Price Up 13% After Strong Earnings

ImmunityBio, Inc. (NASDAQ:IBRX) shot up 13% during trading on Monday following a stronger than expected earnings report. The stock traded as high as $11.00 and last traded at $9.83. 85,988,851 shares changed hands during trading, an increase of 95% from the average session volume of 44,149,879 shares. The stock had previously closed at $8.70.

The company reported ($0.06) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.08) by $0.02. The company had revenue of $38.29 million during the quarter.

More ImmunityBio News

Here are the key news stories impacting ImmunityBio this week:

• Positive Sentiment: Company reported roughly 700% year‑over‑year revenue growth driven by ANKTIVA (bladder cancer) sales and said ANKTIVA approvals have expanded into lung cancer with commercial partnerships across ~33 countries — this is the primary catalyst for the rally. ImmunityBio Reports 700% Year-Over-Year Revenue Growth
• Positive Sentiment: Q4 results: EPS loss of ($0.06) beat the consensus loss of ($0.08) and revenue (~$38.3M) topped estimates — investors are rewarding the top‑line surprise driven by product sales. ImmunityBio (IBRX) Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: An analyst at D. Boral Capital reaffirmed a “buy” rating and set a $23 price target, signaling strong analyst enthusiasm and adding to buying interest. Analyst Reaffirms Buy at D. Boral Capital
• Neutral Sentiment: Management commentary and media pieces highlighted multi‑year expansion plans for ANKTIVA and hinted at potential broader oncology applications — bullish in tone but forward‑looking and dependent on execution and regulatory clearance. Chairman Teases ANKTIVA Expansion Plans
• Negative Sentiment: Despite the beats and revenue surge, the company is still reporting GAAP losses (EPS negative) and remains an early commercial-stage biotech — ongoing profitability, milestone execution, and potential dilution remain material risks. Q4 Loss Details

Analysts Set New Price Targets

Several equities research analysts have recently commented on IBRX shares. The Goldman Sachs Group reaffirmed a “buy” rating on shares of ImmunityBio in a research report on Monday. BTIG Research lifted their price objective on ImmunityBio from $6.00 to $9.00 and gave the company a “buy” rating in a research report on Thursday, January 22nd. Jefferies Financial Group boosted their price objective on ImmunityBio from $8.00 to $9.00 and gave the company a “buy” rating in a research note on Friday, December 12th. HC Wainwright restated a “buy” rating and set a $15.00 target price on shares of ImmunityBio in a research note on Monday. Finally, Piper Sandler lifted their price target on shares of ImmunityBio from $5.00 to $7.00 and gave the company an “overweight” rating in a report on Tuesday, January 20th. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $12.60.

Insider Activity at ImmunityBio

In other ImmunityBio news, Director Christobel Selecky sold 25,000 shares of the stock in a transaction that occurred on Tuesday, January 20th. The shares were sold at an average price of $7.51, for a total transaction of $187,750.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Barry J. Simon sold 151,967 shares of the business’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $7.20, for a total transaction of $1,094,162.40. Following the completion of the transaction, the director directly owned 3,091,604 shares in the company, valued at $22,259,548.80. This trade represents a 4.69% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 226,967 shares of company stock worth $1,531,912 in the last three months. 69.48% of the stock is owned by corporate insiders.

Institutional Trading of ImmunityBio

Institutional investors and hedge funds have recently bought and sold shares of the stock. Walser Wealth Management Company A Ltd Liability Co bought a new position in shares of ImmunityBio during the 4th quarter valued at about $59,000. Invesco Ltd. lifted its position in shares of ImmunityBio by 14.6% in the fourth quarter. Invesco Ltd. now owns 182,836 shares of the company’s stock worth $362,000 after buying an additional 23,353 shares in the last quarter. Corient Private Wealth LLC boosted its stake in ImmunityBio by 69.7% during the fourth quarter. Corient Private Wealth LLC now owns 333,149 shares of the company’s stock valued at $660,000 after buying an additional 136,858 shares during the last quarter. EP Wealth Advisors LLC bought a new position in ImmunityBio during the fourth quarter valued at approximately $35,000. Finally, Empowered Funds LLC purchased a new position in ImmunityBio during the 4th quarter valued at approximately $28,000. 8.58% of the stock is currently owned by institutional investors.

ImmunityBio Trading Up 13.0%

The stock has a 50 day simple moving average of $4.48 and a 200-day simple moving average of $3.12. The firm has a market cap of $9.68 billion, a P/E ratio of -23.98 and a beta of 0.14.

ImmunityBio Company Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.